HBOT for Refractory Osteomyelitis | NorCal Hyperbarics Concord, CA

Osteomyelitis is an infection of bone — most commonly caused by Staphylococcus aureus, including methicillin-resistant strains (MRSA) — that can develop through hematogenous spread (bacteria seeding bone through the bloodstream), direct inoculation from a traumatic injury or surgical procedure, or contiguous spread from an adjacent infected wound or soft tissue infection. Diabetic foot osteomyelitis is particularly prevalent, arising when soft tissue infections in the foot spread to underlying bone, often in the setting of vascular insufficiency that limits healing.

Refractory osteomyelitis is defined as bone infection that persists or recurs despite appropriate surgical débridement and targeted antibiotic therapy — typically because the local tissue environment is too hypoxic to support the mechanisms on which both the immune system and antibiotics depend. Bacteria in chronic osteomyelitis frequently form biofilms: protected communities encased in an extracellular matrix that dramatically reduces antibiotic penetration and shields the organisms from immune detection. This combination of tissue hypoxia and biofilm formation creates a treatment environment in which standard approaches are fundamentally inadequate without addressing the oxygen deficiency.

HBOT is recognized by the Undersea and Hyperbaric Medical Society (UHMS) as an approved indication specifically for refractory osteomyelitis, and is used as an adjunct to — not a replacement for — surgical débridement and antibiotic therapy.

The reason osteomyelitis becomes refractory to standard treatment is fundamentally a problem of oxygen. Infected bone — particularly chronic osteomyelitis — creates a self-perpetuating ischemic environment: bacterial toxins and inflammatory mediators damage the local microvasculature, reducing blood flow and oxygen delivery. In this hypoxic environment, neutrophils lose their bactericidal capacity (leukocyte killing of bacteria is oxygen-dependent), antibiotics work less efficiently, osteoblasts cannot repair the damaged bone matrix, and biofilm-protected bacterial communities thrive undisturbed. HBOT directly breaks this cycle.

At 2.0 to 2.5 atmospheres of 100% oxygen, HBOT raises tissue oxygen tension in infected bone to levels that restore neutrophil function, dramatically increase antibiotic activity (particularly for aminoglycosides, which have substantially improved bacterial killing in hyperoxic conditions), and directly kill anaerobic organisms that cannot survive in high-oxygen environments. HBOT also disrupts bacterial biofilms — the extracellular protein matrices that shield bacteria from both antibiotic penetration and immune recognition — by increasing reactive oxygen species within the biofilm structure.

Simultaneously, the elevated oxygen environment stimulates osteoblast activation, promotes angiogenesis in the avascular segments of infected bone, and provides the metabolic substrate required for bone matrix synthesis and remodeling. Multiple published series have documented superior outcomes in refractory osteomyelitis patients treated with HBOT as an adjunct to surgical débridement and targeted antibiotic therapy, compared to surgery and antibiotics alone. The UHMS officially recognizes refractory osteomyelitis as an approved indication for HBOT. Typical protocols involve 20 to 40 sessions, coordinated with the patient's orthopedic or infectious disease team.